Cargando…
Durable Major Response With Pazopanib in Recurrent, Heavily Pretreated Metastatic Esthesioneuroblastoma Harboring a Fumarate Hydratase Mutation
Autores principales: | Spengler, Marianne, Wheelden, Megan, Mackley, Heath B., Drabick, Joseph J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140788/ https://www.ncbi.nlm.nih.gov/pubmed/34036225 http://dx.doi.org/10.1200/PO.20.00486 |
Ejemplares similares
-
Durable Response to Pazopanib in a Patient with Fumarate Hydratase-Mutant Tubulocystic Renal Cell Carcinoma
por: Othman, Anjum, et al.
Publicado: (2023) -
Heavily Calcified Esthesioneuroblastoma in a 72-year-old
por: Maurer, Robert, et al.
Publicado: (2019) -
HIF and fumarate hydratase in renal cancer
por: Sudarshan, S, et al.
Publicado: (2007) -
Structural basis of fumarate hydratase deficiency
por: Picaud, Sarah, et al.
Publicado: (2011) -
Bevacizumab Demonstrates Prolonged Disease Stabilization in Patients with Heavily Pretreated Metastatic Renal Cell Carcinoma: A Case Series and Review of the Literature
por: Agostino, Nicole M., et al.
Publicado: (2010)